Novel target for therapeutics against Staphylococcus aureus
A leading child expert is warning parents to limit the amount of television children watch before the age of two, after an extensive review published in the January issue of Acta Paediatrica showed that it can do more harm than good to their ongoing development. Professor Dimitri A Christakis, from the Seattle Children’s Research Institute
Full Post: Expert warns parents to limit amount of TV children watch before age of two
Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease.
Their work appears November 28 in the open-access journal PLoS Pathogens .
Once occurring more commonly in healthcare facilities, but now affecting segments of the general population, MRSA is a bacterial pathogen responsible for a range of diseases from mild skin infection to life-threatening sepsis. Even with antibiotics, these infections can still be fatal.
Senior author Magnus Höök, Ph.D. and his colleagues carried out biochemical and structural studies to determine the binding mechanism of clumping factor A (ClfA), a surface protein that plays an important role in the pathogenesis of S. aureus. The group found that ClfA binds to the blood-clotting protein fibrinogen (Fg) at a site that is also responsible for inducing platelet activation and thrombosis (clot inside a blood vessel).
The results show significant structural differences in how staphylococcal and platelet receptor proteins recognize fibrinogen. By exploiting this difference in recognition, the researchers show that agents could be designed that inhibit the ClfA-Fg interaction but do not interfere with the interaction of Fg with the platelet integrin, therefore avoiding unwanted side effects on the circulatory system.
Rates of antibiotic-resistant head and neck infections increased in pediatric patients nationwide between 2001 and 2006, according to a report in the January issue of Archives of Otolaryngology-Head & Neck Surgery. Before the 1980s, infections with strains of the bacteria Staphylococcus aureus resistant to the antibiotic methicillin (methicillin-resistant Staphylococcus aureus, or MRSA) were most often
Full Post: MRSA head and neck infections increase among children
Pre-operative screening of patients for methicillin-resistant Staphylococcus aureus (MRSA) may be an effective way to reduce infection rates following otolaryngic surgeries, according to new research published in the January 2009 issue of Otolaryngology - Head and Neck Surgery. The study, conducted by researchers at the Massachusetts Ear & Eye Infirmary, is the first to review otolaryngic
Full Post: MRSA pre-screening effective in reducing otolaryngic surgical infection rates
An enzyme that lives in Methicillin-resistant Staphylococcus aureus (MRSA) and helps the dangerous bacterium to grow and spread infection through the human body has been visualised for the first time, according to a study out today in Proceedings of the National Academy of Sciences (PNAS). Now, armed with detailed information about the structure of
Full Post: MRSA’s weak point visualised by scientists
The U.S. Food and Drug Administration has licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding. People with congenital fibrinogen deficiency are unable to make sufficient amounts of fibrinogen, which plays
Full Post: FDA approves RiaSTAP for bleeding in patients with congenital fibrinogen deficiency
Targanta Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the November 19, 2008 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. AIDAC will review Targanta’s New Drug Application (NDA) for oritavancin for the treatment of complicated skin and skin structure infection (cSSSI) caused by gram-positive
Full Post: Targanta Therapeutics announces posting of briefing documents for review of FDA